Buprenorphine and Cyclosporine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Cyclosporine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Cyclosporine can slow down the liver enzyme (called CYP3A4) that normally breaks down your buprenorphine. When that enzyme is slowed, more buprenorphine can build up in your body. That can make its effects stronger and last longer, including more sleepiness and, in more serious cases, slowed breathing.
The good news is your care team can manage this. They may fine-tune your buprenorphine dose and keep a closer eye on you. Please don't stop or change either medicine on your own. Just let your pharmacist or doctor know you take both, and tell them right away if you feel unusually drowsy, foggy, or short of breath.
Mechanism: Cyclosporine inhibits CYP3A4, the primary enzyme metabolizing buprenorphine. Neither agent is a prodrug here, so inhibition raises buprenorphine exposure (increased plasma concentration/AUC).
Effect: Prolonged opioid effects including sedation and respiratory depression. Severity major; evidence probable; onset unspecified.
Management:
- If starting cyclosporine, consider reducing buprenorphine dose until stable; monitor sedation and respiratory status frequently.
- On cyclosporine discontinuation, anticipate needing a buprenorphine dose increase; monitor for withdrawal.
- For fixed-dose formulations (subQ, transdermal), if dose cannot be adjusted, consider transitioning to a titratable formulation.
- Monitor subQ buprenorphine patients for over-medication when adding cyclosporine.
What happens
Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
Because buprenorphine plasma concentrations rise when it is taken together with a CYP3A4 inhibitor, extended opioid effects such as respiratory depression can result. When a patient on buprenorphine requires a CYP3A4 inhibitor, it may be appropriate to lower the buprenorphine dose until drug effects stabilize, while checking often for sedation and respiratory depression. Conversely, if a CYP3A4 inhibitor is stopped in a patient being treated with buprenorphine, an increase in the buprenorphine dose should be considered until stable effects are reached, with monitoring for indications of opioid withdrawal2. Should dosage modification not be feasible once the CYP3A4 inhibitor is gone, the patient should be switched back to a buprenorphine formulation that allows finer dose control. For patients moved from a regimen combining transmucosal buprenorphine with CYP3A4 inhibitors, verify that the plasma buprenorphine level delivered by subQ buprenorphine is sufficient. In those already receiving subQ buprenorphine who then need a CYP3A4 inhibitor, watch for indications of over-medication. Where signs and symptoms of buprenorphine toxicity or overdose appear yet the co-administered drug cannot be lowered or stopped, decrease the buprenorphine dose. If the doses on hand do not allow the target dose to be reached, stop treatment and manage the patient with a buprenorphine formulation that offers more precise dose adjustment 1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. This combination is manageable with the right adjustments and monitoring.
- Your team may lower your buprenorphine dose while you're on cyclosporine, then raise it back if cyclosporine is stopped. The dose may need to be adjusted and individualized by your care team.
- They may monitor you more closely for sedation and slowed breathing.
- If you use a fixed-dose form (like a patch or injection), they may switch you to a form that's easier to fine-tune.
Tell your pharmacist or doctor if you feel very drowsy, confused, or short of breath, or if you notice withdrawal symptoms after any change.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) The impact of concurrently administered CYP3A4 inhibitors on buprenorphine exposure in patients receiving subQ buprenorphine has not been evaluated; nevertheless, these interactions have been demonstrated in studies that used transmucosal buprenorphine. Buprenorphine's effects may vary according to the route of administration 1.
Common questions
Can I take Buprenorphine and Cyclosporine together?
Cyclosporine can raise buprenorphine levels by slowing its breakdown, increasing sedation and breathing-slowdown risk. Keep taking both as prescribed and ask your care team to adjust the buprenorphine dose and watch you closely. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Cyclosporine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Cyclosporine interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. This combination is manageable with the right adjustments and monitoring. Your team may lower your buprenorphine dose while you're on cyclosporine, then raise it back if cyclosporine is stopped. The dose may need to be adjusted and individualized by your care team. They may monitor you more closely for sedation and… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Cyclosporine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Cyclosporine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist